论文部分内容阅读
目的探讨缬沙坦联合银杏达莫注射液在早期糖尿病肾病患者中的疗效和安全性,旨在为规范早期糖尿病肾病的临床治疗方案提供参考依据。方法选择2010年3月至2012年3月在我院内分泌科住院治疗的188例早期糖尿病肾病患者为研究对象,应用随机数字表法将本研究入选患者分为两组,即对照组和治疗组,每组各89例,对照组患者给予缬沙坦,治疗组患者则在上述治疗的基础上加用银杏达莫注射液进行治疗,观察对照组和治疗组患者临床疗效和不良反应发生情况。结果治疗组治疗总有效率(97.85%)明显高于对照组的(90.32%),治疗总有效率差异有统计学意义(χ2=4.735,P<0.05),且对照组和治疗组患者均未见过敏性皮疹、过敏性休克、恶心、呕吐、头晕、头痛、头晕、疲乏、腹痛、干咳、体位性血压、腹泻、鼻炎、咽炎和关节痛等不良反应,血尿常规、血糖血脂、电解质和肝肾功能等检查也未见明显异常,对照组和治疗组患者在不良反应发生率差异无统计学意义(P>0.05)。结论缬沙坦联合银杏达莫注射液方案治疗早期糖尿病肾病临床疗效确切,安全可靠,不良反应少,值得进一步推广运用,改善早期糖尿病肾病患者的预后。
Objective To investigate the efficacy and safety of valsartan combined with ginkgo dipyridamole injection in patients with early diabetic nephropathy and to provide a reference for standardizing the clinical treatment of diabetic nephropathy in early stage. Methods From March 2010 to March 2012, 188 patients with early diabetic nephropathy hospitalized with endocrinology in our hospital were enrolled. Patients in this study were divided into two groups according to random number table method: control group and treatment group , 89 cases in each group. Patients in the control group were given valsartan. Patients in the treatment group were treated with Yinxingdamo injection on the basis of the above treatment, and the clinical efficacy and adverse reactions in the control group and the treatment group were observed. Results The total effective rate (97.85%) in the treatment group was significantly higher than that in the control group (90.32%), the total effective rate was statistically different (χ2 = 4.735, P <0.05), and neither the control group nor the treatment group See the allergic skin rash, anaphylactic shock, nausea, vomiting, dizziness, headache, dizziness, fatigue, abdominal pain, dry cough, orthostatic blood pressure, diarrhea, rhinitis, pharyngitis and joint pain and other adverse reactions, blood and urine, blood glucose, electrolytes and liver No significant abnormal renal function tests, the control group and treatment group patients in the incidence of adverse reactions was no significant difference (P> 0.05). Conclusion Valsartan combined with gingko Damo injection solution for the treatment of early diabetic nephropathy is effective, safe and reliable with few adverse reactions. It is worth further promotion and application to improve the prognosis of patients with early diabetic nephropathy.